These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35801373)

  • 1. Low-grade serous carcinoma detected from intraoperative peritoneal washings: Cytological findings and detection of KRAS mutation.
    Yamamoto E; Warigaya K; Kinoshita Y; Yamamoto A; Murata SI
    Cancer Rep (Hoboken); 2022 Oct; 5(10):e1676. PubMed ID: 35801373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
    Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
    J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
    Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
    Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary.
    Xu Y; Bi R; Xiao Y; Tu X; Li M; Li A; Shan L; Zhou S; Yang W
    Diagn Pathol; 2017 Dec; 12(1):87. PubMed ID: 29273082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
    Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
    BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
    Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
    Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osseous Metaplasia in Low-grade Ovarian Serous Carcinoma With a BRAF Mutation: A Case Report.
    Catteau X; Preat F; D'haene N; Noël JC
    Int J Gynecol Pathol; 2021 Sep; 40(5):448-451. PubMed ID: 33252399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion.
    Yemelyanova A; Mao TL; Nakayama N; Shih IeM; Kurman RJ
    Am J Surg Pathol; 2008 Dec; 32(12):1800-6. PubMed ID: 18779727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
    Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
    J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.
    Manning-Geist B; Gordhandas S; Liu YL; Zhou Q; Iasonos A; Da Cruz Paula A; Mandelker D; Long Roche K; Zivanovic O; Maio A; Kemel Y; Chi DS; O'Cearbhaill RE; Aghajanian C; Weigelt B; Chui MH; Grisham RN
    Clin Cancer Res; 2022 Oct; 28(20):4456-4465. PubMed ID: 35443055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
    Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
    J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
    Cobb LP; Sun CC; Iyer R; Nick AM; Fleming ND; Westin SN; Sood AK; Wong KK; Silva EG; Gershenson DM
    Gynecol Oncol; 2020 Sep; 158(3):653-658. PubMed ID: 32709538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
    Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
    Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma?
    Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y
    Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum of
    Chui MH; Chang JC; Zhang Y; Zehir A; Schram AM; Konner J; Drilon AE; Da Cruz Paula A; Weigelt B; Grisham RN
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34568720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characteristics of low-grade serous carcinoma in effusions.
    Doutel D; Davidson B; Nitschke Pettersen IK; Torgunrud A
    Cytopathology; 2023 Mar; 34(2):99-105. PubMed ID: 36609991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of 103 ovarian serous and mucinous tumors.
    Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
    Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
    Zhu YF; He LS; Zhang ZD; Huang QS
    Asian Pac J Trop Med; 2012 Dec; 5(12):925-30. PubMed ID: 23199707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.